Consensus I-Mab Deutsche Boerse AG

Equities

0VY

US44975P1030

Real-time Estimate Tradegate Other stock markets 19:58:31 27/06/2024 BST			5-day change	1st Jan Change
1.555 ^EUR	-2.20%		-1.26%	-4.85%

06-06	I-Mab Appoints Phillip Dennis as Chief Medical Officer	CI
06-05	I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	MT

Evolution of the average Target Price on I-Mab

Price target over the last 5 years

History of analyst recommendation changes

1dc5d1ea158167f0b0fea2500b6c0a.fXRF8bRNEzaFZm4ZytrXep5PUSmfS_2tZVGvtWFjbd8.Gx8og-58ZFvsJDZArrPlIu8GNBr-KKmfXD7n4xUoHq4iGAC55iF8W9EgGQ~1dd611af9ad6da91ded60e755ab2ba94

Analyst Recommendations on I-Mab

Piper Sandler Adjusts Price Target on I-Mab to $10 From $15, Maintains Overweight Rating	03-18	MT
Needham Cuts Price Target on I-Mab to $6 From $8, Maintains Buy Rating	03-15	MT
Needham Trims I-Mab Price Target to $23 From $24, Maintains Buy Rating	25/09/23	MT
HC Wainwright Adjusts Price Target on I-Mab to $18 From $25, Maintains Buy Rating	18/08/23	MT
Needham Lowers Price Target on I-Mab to $24 From $33, Maintains Buy Rating	03/04/23	MT
Piper Sandler Adjusts Price Target on I-Mab to $25 From $30, Maintains Overweight Rating	03/04/23	MT
HC Wainwright Adjusts Price Target on I-Mab to $25 From $45, Maintains Buy Rating	03/04/23	MT
I-Mab Says Combination Treatment for Myelodysplastic Syndrome Showed Overall Response Rate of 86.7% in Phase 2 Trial	12/09/22	MT
HC Wainwright Adjusts I-Mab's Price Target to $45 From $70, Maintains Buy Rating	31/08/22	MT
Needham Adjusts I-Mab's Price Target to $33 From $41, Reiterates Buy Rating	31/08/22	MT
Piper Sandler Adjusts I-Mab's Price Target to $30 From $35, Reiterates Overweight Rating	31/08/22	MT
Needham Lowers I-Mab's Price Target to $41 From $72, Maintains Buy Rating	17/08/22	MT
HC Wainwright Adjusts I-Mab's Price Target to $70 From $80, Keeps Buy Rating	31/05/22	MT
Piper Sandler Adjusts I-Mab's Price Target to $35 From $80, Reiterates Overweight Rating	31/05/22	MT
Needham Adjusts I-Mab's Price Target to $72 From $85, Reiterates Buy Rating	31/05/22	MT
HC Wainwright Adjusts I-Mab's Price Target to $80 from $95, Keeps Buy Rating	30/03/22	MT
Piper Sandler Adjusts I-Mab's Price Target to $80 From $90, Reiterates Overweight Rating	30/03/22	MT
SWS Research Starts I-Mab at Buy with $96 Price Target	09/12/21	MT
Needham Adjusts Price Target on I-Mab to $85 from $83, Keeps Buy Rating	01/11/21	MT
I MAB : HC Wainwright Adjusts I-Mab's Price Target to $95 from $75, Keeps Buy Rating	01/09/21	MT
I MAB : Cantor Fitzgerald Adjusts I-Mab PT to $95 From $90, Maintains Overweight Rating	13/07/21	MT
I MAB : Cantor Fitzgerald Adjusts I-Mab's Price Target to $90 From $76, Maintains Overweight Rating	10/06/21	MT
I MAB : Piper Sandler Adjusts I-Mab PT to $90 From $75, Maintains Overweight Rating	07/06/21	MT
I MAB : Daiwa Securities Initiates Coverage on I-Mab With Buy Rating	02/06/21	MT
I MAB : Needham Starts I-Mab at Buy With $75 Price Target	15/03/21	MT